Going ForwardThis was the first time I can recall Paul being foreceful in a meeting on identifying the valuation gap and their need to get a fair value for the pipeline. He even mentioned other small biotechs in that regard. Hopefully LifSci can get them up to industry best-practices in how to achieve that with what they have and explaining it properly and highlighting the valuation proposition factually. I think this boards identification of the importance of this issue is why that was discussed at all.
If they do add the Board seat as they has said they would, I would like to think that the >20% of withheld votes for Littlejohn and Lacoste is enough of an indication that they lack full support and would step off. Self-respect and an appreciation for the small size of the company and good governance would be enough for most board members who had 20% fewer votes to step down when the Board expands and the timing is right. Let's see what happens.